About Investors Technology Products News Contact Results you can bank on. LEARN HOW MIRIAD IS HELPING TISSUE BANKS REDUCE DISCARDS BY 40% Get to know our amazingly versatile and unique RVF® technology Our Products in Action Reveal Single Tests FDA-approved, MedMira’s Reveal G4 provides instant HIV results. Learn More > Multiplo Multiplex Tests MedMira’s Multiplo multiplex tests include combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis. Learn More > Miriad Research Tools Miriad includes toolkits to develop new diagnostic tests and commercialized combination tests. Learn More > About MedMira MedMira is dedicated to improving human health by providing the best in rapid diagnostics. Our patented Rapid Vertical Flow Technology™ delivers fast, accurate results for a range of applications—helping care providers and their patients know more, instantly. MedMira News > Management’s Discussion & Analysis For the nine months ended April 30, 2021 Condensed Interim Consolidated Financial Statements For the nine months ended April 30, 2021 and April 30, 2020 (Unaudited – Prepared by Management) Management’s Discussion & Analysis For the six months ended January 31, 2021 Condensed Interim Consolidated Financial Statements For the six months ended January 31, 2021 and January 31, 2020 (Unaudited – Prepared by Management) Product and Regulatory Update on MedMira’s COVID-19 Product Family Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan. Progress Update on MedMira’s COVID-19 Product Family Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the severe COVID-19 symptom presentation or future SARS-CoV-2 reinfection. Not all antibodies can block the virus from infecting the patient, and, according to the recent reports, the levels of neutralizing antibodies vary, so as the potency of the antibody protection. MedMira Announces Product Update Halifax, Nova Scotia, 30 December, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19™ PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19™ PLUS Total Antibody Test is an update to MedMira’s REVEALCOVID-19™ Total Antibody Test that addresses the total antibody testing demands arising from recent developments in COVID-19 vaccines across global markets. MedMira Reports First Quarter Results FY2021 Halifax, Nova Scotia, December 24, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020. MedMira’s July Update as per the IIROC Request Halifax, Nova Scotia, 10 July, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) would like to issue a statement to address the request form the Investment Industry Regulatory Organization of Canada (IIROC) and comment on the recent increase in the price of the company’s shares. MedMira is not aware of any material change in its business affairs that has not been publicly disclosed and could account for the recent increase in market activity. MedMira Reports Third Quarter Results FY2020 Halifax, Nova Scotia, June 29, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020. Message from MedMira’s CEO In a short time, MedMira has developed an RVF®-based rapid test that detects total antibodies to the SARS-CoV-2 virus, the causative agent of COVID-19, in human serum, plasma and venipuncture whole blood. Despite our financial constraints, MedMira, relying solely on our dedicated team and stakeholders, was able to develop and validate the newest member of our Reveal family, REVEALCOVID-19™ Total Antibody Test. MedMira Announces Exclusive Distribution Partnership with Webb Diagnostic Technologies and Initial Order for REVEALCOVID-19™ Total Antibody Test in the U.S. Halifax, Nova Scotia, 27 May, 2020 – MedMira Inc. (MedMira) (TSXV: MIR) announces that company has entered into an Exclusive Distribution Agreement with Webb Diagnostic Technologies, Inc., (WebbDX) for the distribution of MedMira’s REVEALCOVID-19™ Total Antibody Test. Webb Diagnostic Technologies has placed the first order with the purchase value of approximately CDN$3.5 million. The Company has received the down payment to initiate the production process. MedMira Announces Progress Update of its REVEALCOVID-19TM Total Antibody test including CE mark Halifax, Nova Scotia, 21. May, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID-19 TM Total Antibody Test. CONTACT US | LEGAL INFO | NEWS & EVENTS ©2020 MedMira Inc. All Rights Reserved. Follow us on